

Prior Authorization Annual Review - Fiscal Year 2008

Ultram ER and Ultram ODT

Oklahoma Health Care Authority
September 2008

Manufacturer: Biovail Corporation
Distributor: PriCara, Unit of Ortho-McNeil, Inc
Classification: Centrally acting synthetic opioid analgesic
Status: Prescription only

Summary:

Ultram® ER is an extended release form of tramadol. It is indicated for the treatment of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time (up to 300mg/day).

Ultram® ODT* is an orally disintegrating formulation of tramadol. It is indicated for the treatment of moderate to moderately severe pain in adults and will be available in a 50mg dosage form.

*Ultram ODT (not yet available)

Current Criteria

Ultram ER® (FDA approved 09-08-2005)

- FDA approved diagnosis.
- Clinical supporting information for a diagnosis or health condition that requires extended pain treatment with around-the-clock dosing schedule, and the reason immediate release tramadol is inappropriate. Must include the prescriber's signature.
- Maximum covered dose of 300mg daily due to lack of efficacy and increased risk of adverse effects and seizures at higher doses.
- Quantity limit of 30 units per 30 days.

Ultram ODT® (FDA approved 05-05-2005)

- FDA approved diagnosis
- Clinical supporting information indicating a medical condition which would make a member incapable of swallowing tablets and must include prescriber's signature
- Quantity limit of 240 units per 30 days.

Approvals will be for 90 days, with the exception of members with a cancer related diagnosis where an approval will be granted for one year.

Utilization FY '08

From July 1, 2007 to June 30, 2008 a total of 14,859 members received tramadol products through the SoonerCare pharmacy program for fiscal year 2008.

Product	# of Claims	Total Units	Total Days	Units/Day	Total Cost	Total Members	Per Diem
Ultram 50mg	1	100	15	6.67	\$121.72	1	\$8.11
Tramadol 50mg	34,808	2,417,953	551,847	4.38	\$319,869.52	14,847	\$0.58
Ultram ER 100mg	19	533	533	1	\$1,636.41	8	\$3.07
Ultram ER 200mg	47	1,540	1,540	1	\$7,094.27	19	\$4.61
Ultram ER 300mg	35	1,022	1,022	1	\$7,240.72	10	\$7.08
Total	34,910	2,421,148	554,957		\$335,962.64	*14,859	\$0.61

*Total unduplicated members for FY08.

Utilization Trends

Total Cost FY '08	\$335,962.64	↑ 30.7 %
<i>Total Cost FY '07</i>	<i>\$256,965.72</i>	
Total Claims FY '08	34,910	↑ 10.3%
<i>Total Claims FY '07</i>	<i>31,638</i>	
Total Members FY '08	14,859	↑ 9.5%
<i>Total Members FY '07</i>	<i>13,563</i>	
Per Diem FY '08	\$0.61	↑ 15.1%
<i>Per Diem FY '07</i>	<i>\$0.53</i>	

Total petitions received for this category during the fiscal year:

Approved	35
Denied	148
Incomplete	45

Demographics

Claims were reviewed to determine the age/gender of the members.

FY '08

Age	Female	Male	Totals
0 to 9	20	45	65
10 to 19	1,722	1,167	2,889
20 to 34	3,839	620	4,459
35 to 49	2,867	879	3,746
50 to 64	2,124	912	3,036
65 to 79	192	84	276
80 to 94	13	3	16
95 and Over	3	0	3
Unknown	0	0	369
Totals	10,780	3,710	14,859

Recommendations

The College of Pharmacy recommends no changes at this time.